Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Double Umbilical Cord Blood Transplantation in High-Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance.

Kalin B, Ter Borg M, Wijers R, Somers JAE, van der Holt B, van Bergen CAM, Petersen EJ, Kuball J, Meijer E, Schaap NPM, Zeerleder SS, Broers AE, Braakman E, Falkenburg JHF, Lamers CHJ, Cornelissen JJ.

Hemasphere. 2019 Aug 9;3(5):e285. doi: 10.1097/HS9.0000000000000285. eCollection 2019 Oct. No abstract available.

2.

Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality.

Shouval R, de Jong CN, Fein J, Broers AEC, Danylesko I, Shimoni A, Reurs MR, Baars AE, van der Schaft N, Nagler A, Cornelissen JJ.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1685-1691. doi: 10.1016/j.bbmt.2018.05.005. Epub 2018 May 9.

3.

Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals.

Atiq F, Hameli E, Broers AEC, Doorduijn JK, Van Gelder T, Andrews LM, Koch BCP, Versmissen J, de Winter BCM.

Eur J Clin Pharmacol. 2018 Jun;74(6):767-773. doi: 10.1007/s00228-018-2434-4. Epub 2018 Mar 2.

4.

Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience.

De Jong CN, Saes L, Klerk CPW, Van der Klift M, Cornelissen JJ, Broers AEC.

PLoS One. 2017 Oct 26;12(10):e0187184. doi: 10.1371/journal.pone.0187184. eCollection 2017.

5.

QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors.

Berger FA, Monadian N, de Groot NMS, Santbergen B, van der Sijs H, Becker ML, Broers AEC, van Gelder T, van den Bemt PMLA.

Br J Clin Pharmacol. 2018 Feb;84(2):369-378. doi: 10.1111/bcp.13457. Epub 2017 Dec 6.

6.

The management of critically ill patients with haematological malignancies.

Kusadasi N, Müller MCA, van Westerloo DJ, Broers AEC, Hilkens MGEC, Blijlevens On Behalf Of The Hema-Icu Study Group NMA.

Neth J Med. 2017 Sep;75(7):265-271. Review.

7.

Five Phases of Recovery and Rehabilitation After Allogeneic Stem Cell Transplantation: A Qualitative Study.

van der Lans MCM, Witkamp FE, Oldenmenger WH, Broers AEC.

Cancer Nurs. 2019 Jan/Feb;42(1):50-57. doi: 10.1097/NCC.0000000000000494.

PMID:
28426538
8.

Response: Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting.

Atiq F, Broers AE, Andrews LM, Doorduijn JK, Koch BC, Van Gelder T, Versmissen J.

Eur J Clin Pharmacol. 2016 Dec;72(12):1539-1540. Epub 2016 Aug 25. No abstract available.

PMID:
27561268
9.

A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib.

Atiq F, Broers AE, Andrews LM, Doorduijn JK, Koch BC, Van Gelder T, Versmissen J.

Eur J Clin Pharmacol. 2016 Jun;72(6):719-23. doi: 10.1007/s00228-016-2038-9. Epub 2016 Mar 11.

10.

Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.

Slot S, Smits K, van de Donk NW, Witte BI, Raymakers R, Janssen JJ, Broers AE, Te Boekhorst PA, Zweegman S.

Bone Marrow Transplant. 2015 Nov;50(11):1424-31. doi: 10.1038/bmt.2015.172. Epub 2015 Aug 3.

PMID:
26237165
11.

Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells.

Te Boome LC, Mansilla C, van der Wagen LE, Lindemans CA, Petersen EJ, Spierings E, Thus KA, Westinga K, Plantinga M, Bierings M, Broers AE, Cuijpers ML, van Imhoff GW, Janssen JJ, Huisman C, Zeerleder S, Huls G, Boelens JJ, Wulffraat NM, Slaper-Cortenbach IC, Kuball J.

Leukemia. 2015 Sep;29(9):1839-46. doi: 10.1038/leu.2015.89. Epub 2015 Apr 3.

PMID:
25836589
12.

Insufficient recovery of thymopoiesis predicts for opportunistic infections in allogeneic hematopoietic stem cell transplant recipients.

Wils EJ, van der Holt B, Broers AE, Posthumus-van Sluijs SJ, Gratama JW, Braakman E, Cornelissen JJ.

Haematologica. 2011 Dec;96(12):1846-54. doi: 10.3324/haematol.2011.047696. Epub 2011 Aug 22.

13.

IL-7-mediated protection against minor-antigen-mismatched allograft rejection is associated with enhanced recovery of regulatory T cells.

Broers AE, Bruinsma M, Posthumus-van Sluijs SJ, Wils EJ, Spits H, Löwenberg B, Braakman E, Cornelissen JJ.

Haematologica. 2007 Aug;92(8):1099-106.

14.

Flt3 ligand expands lymphoid progenitors prior to recovery of thymopoiesis and accelerates T cell reconstitution after bone marrow transplantation.

Wils EJ, Braakman E, Verjans GM, Rombouts EJ, Broers AE, Niesters HG, Wagemaker G, Staal FJ, Löwenberg B, Spits H, Cornelissen JJ.

J Immunol. 2007 Mar 15;178(6):3551-7.

15.
16.

Interleukin-7 improves T-cell recovery after experimental T-cell-depleted bone marrow transplantation in T-cell-deficient mice by strong expansion of recent thymic emigrants.

Broers AE, Posthumus-van Sluijs SJ, Spits H, van der Holt B, Löwenberg B, Braakman E, Cornelissen JJ.

Blood. 2003 Aug 15;102(4):1534-40. Epub 2003 Apr 24.

PMID:
12714515
17.

Quantification of newly developed T cells in mice by real-time quantitative PCR of T-cell receptor rearrangement excision circles.

Broers AE, Meijerink JP, van Dongen JJ, Posthumus SJ, Löwenberg B, Braakman E, Cornelissen JJ.

Exp Hematol. 2002 Jul;30(7):745-50.

PMID:
12135672
18.

Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation.

Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V, Löwenberg B, Cornelissen JJ.

Blood. 2000 Apr 1;95(7):2240-5.

PMID:
10733491

Supplemental Content

Loading ...
Support Center